HUE044038T2 - Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával - Google Patents

Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával

Info

Publication number
HUE044038T2
HUE044038T2 HUE16163440A HUE16163440A HUE044038T2 HU E044038 T2 HUE044038 T2 HU E044038T2 HU E16163440 A HUE16163440 A HU E16163440A HU E16163440 A HUE16163440 A HU E16163440A HU E044038 T2 HUE044038 T2 HU E044038T2
Authority
HU
Hungary
Prior art keywords
antibodies
methods
ankylosing spondylitis
treating ankylosing
treating
Prior art date
Application number
HUE16163440A
Other languages
English (en)
Inventor
Shepard Mpofu
Hanno Richards
Karthinathan Thangavelu
Matthias Machacek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE044038(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE044038T2 publication Critical patent/HUE044038T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
HUE16163440A 2010-11-05 2011-11-04 Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával HUE044038T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41053310P 2010-11-05 2010-11-05

Publications (1)

Publication Number Publication Date
HUE044038T2 true HUE044038T2 (hu) 2019-09-30

Family

ID=44906168

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16163440A HUE044038T2 (hu) 2010-11-05 2011-11-04 Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával

Country Status (27)

Country Link
US (9) US9744234B2 (hu)
EP (6) EP2635303A2 (hu)
JP (7) JP2014503482A (hu)
KR (5) KR20180129991A (hu)
CN (2) CN104800844A (hu)
AU (1) AU2011325134B2 (hu)
BR (1) BR112013011176A2 (hu)
CA (2) CA3116725C (hu)
CL (1) CL2013001213A1 (hu)
CY (1) CY1121802T1 (hu)
DE (1) DE20187001T1 (hu)
DK (1) DK3111954T3 (hu)
ES (2) ES2804624T1 (hu)
HR (1) HRP20191162T1 (hu)
HU (1) HUE044038T2 (hu)
IL (4) IL311014A (hu)
LT (1) LT3111954T (hu)
MA (1) MA34647B1 (hu)
MX (1) MX362591B (hu)
PL (1) PL3111954T3 (hu)
PT (1) PT3111954T (hu)
RU (1) RU2582937C2 (hu)
SG (2) SG10201505624VA (hu)
SI (1) SI3111954T1 (hu)
TR (1) TR201909531T4 (hu)
TW (3) TWI618543B (hu)
WO (1) WO2012059598A2 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
HUE044038T2 (hu) * 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CN108948196B (zh) 2011-10-11 2022-09-23 维埃拉生物股份有限公司 Cd40l-特异性tn3-衍生的支架及其使用方法
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
US9688769B2 (en) * 2013-10-22 2017-06-27 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
KR20160113268A (ko) * 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
LT3142751T (lt) 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
FR3021976B1 (fr) * 2014-06-06 2018-11-02 Hospices Civils De Lyon Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
WO2015191760A2 (en) * 2014-06-10 2015-12-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
ES2981697T3 (es) * 2014-09-10 2024-10-10 Novartis Ag Uso de antagonistas de IL-17 para inhibir la progresión del daño estructural en pacientes con artritis psoriásica
WO2016064817A1 (en) * 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2016226414B2 (en) 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN108367074A (zh) * 2015-10-19 2018-08-03 诺华股份有限公司 使用白介素-17（il-17）拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
CN109641031A (zh) * 2016-08-23 2019-04-16 德国杰特贝林生物制品有限公司 预防与c1酯酶抑制剂缺乏相关的遗传性血管性水肿急性发作的方法
JP2021501752A (ja) * 2017-11-02 2021-01-21 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
KR20210008847A (ko) * 2018-05-09 2021-01-25 노파르티스 아게 카나키누맙의 용도
CN113474364A (zh) * 2018-09-26 2021-10-01 维埃拉生物股份有限公司 Cd40l拮抗剂及其用途
WO2020154252A1 (en) * 2019-01-22 2020-07-30 Genentech, Inc. Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
EP4061418A1 (en) 2019-11-19 2022-09-28 Novartis AG Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
US20240101659A1 (en) * 2020-11-25 2024-03-28 Dr. Reddy’S Laboratories Limited Stable therapeutic protein formulation and methods of making the same
WO2022144023A1 (zh) * 2021-01-04 2022-07-07 江苏恒瑞医药股份有限公司 抗il-17抗体治疗自身免疫性疾病和炎症的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) * 2021-03-29 2021-12-13 김지혜 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
WO2022271544A1 (en) * 2021-06-21 2022-12-29 Bristol-Myers Squibb Company Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products
CN114306594A (zh) * 2021-12-21 2022-04-12 华中科技大学同济医学院附属协和医院 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
WO2024156841A1 (en) 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
EP2261335B1 (en) 1998-11-27 2017-06-14 UCB Pharma S.A. Compositions and methods for increasing bone mineralisation
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
WO2003041637A2 (en) 2001-11-09 2003-05-22 Centocor, Inc. Lyophilized monoclonal antibody compositions
EP2277522B1 (en) 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP3936365B2 (ja) 2004-09-14 2007-06-27 ソニーケミカル＆インフォメーションデバイス株式会社 機能素子実装モジュール及びその製造方法
CN103861102A (zh) * 2005-03-08 2014-06-18 辉瑞产品公司 抗ctla-4 抗体组合物
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTFZ INHIBITORS
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
BRPI0706788A2 (pt) * 2006-01-31 2011-04-05 Novartis Ag anticorpos antagonistas il-17
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
BRPI0714893A2 (pt) 2006-09-05 2013-05-28 Medarex Inc anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
EP2114435A1 (en) 2007-02-02 2009-11-11 Novartis AG Modulators of sclerostin binding partners for treating bone-related disorders
US7744874B2 (en) 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
EA200970880A1 (ru) 2007-03-22 2010-02-26 Имклоун Элэлси Стабильные композиции на основе антител
WO2008121616A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles
AU2008266745B2 (en) * 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011506483A (ja) 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
EP2321422A4 (en) 2008-07-08 2013-06-19 Abbvie Inc PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
MX2011003184A (es) 2008-09-29 2011-04-21 Roche Glycart Ag Anticuerpos contra il17 humana y usos de los mismos.
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
FR2938547B1 (fr) 2008-11-14 2012-11-16 Total Raffinage Marketing Liant synthetique clair
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
HUE044038T2 (hu) * 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法

Also Published As

Publication number Publication date
CA3116725C (en) 2023-10-24
US20220193234A1 (en) 2022-06-23
AU2011325134A1 (en) 2013-04-04
US20200276305A1 (en) 2020-09-03
CA2813849A1 (en) 2012-05-10
EP3111954B1 (en) 2019-04-03
DE20187001T1 (de) 2021-04-01
JP2016065094A (ja) 2016-04-28
KR20180019247A (ko) 2018-02-23
US20210177966A1 (en) 2021-06-17
CA3116725A1 (en) 2012-05-10
AU2011325134B2 (en) 2014-10-23
TWI618543B (zh) 2018-03-21
TW201726170A (zh) 2017-08-01
PT3111954T (pt) 2019-07-10
JP2019142912A (ja) 2019-08-29
MX362591B (es) 2019-01-25
IL262559A (en) 2018-12-31
ES2804624T1 (es) 2021-02-08
EP3912640A1 (en) 2021-11-24
CL2013001213A1 (es) 2014-03-28
EP3111954A1 (en) 2017-01-04
WO2012059598A3 (en) 2012-09-27
EP2635303A2 (en) 2013-09-11
TWI604851B (zh) 2017-11-11
KR20140008305A (ko) 2014-01-21
KR20150020734A (ko) 2015-02-26
MX2013005060A (es) 2013-06-28
US11534491B2 (en) 2022-12-27
ES2733712T3 (es) 2019-12-02
JP6049843B2 (ja) 2016-12-21
TR201909531T4 (tr) 2019-07-22
PL3111954T3 (pl) 2019-10-31
CN104800844A (zh) 2015-07-29
JP6250109B2 (ja) 2017-12-20
SG189138A1 (en) 2013-05-31
KR20160067984A (ko) 2016-06-14
IL225309A0 (en) 2013-06-27
TWI616204B (zh) 2018-03-01
US20190307880A1 (en) 2019-10-10
IL262559B (en) 2022-06-01
CA2813849C (en) 2021-06-15
JP2014503482A (ja) 2014-02-13
IL311014A (en) 2024-04-01
EP3542820A1 (en) 2019-09-25
EP3757126A1 (en) 2020-12-30
KR20180129991A (ko) 2018-12-05
US20230346926A1 (en) 2023-11-02
SG10201505624VA (en) 2015-09-29
MA34647B1 (fr) 2013-11-02
JP2018065826A (ja) 2018-04-26
TW201306864A (zh) 2013-02-16
WO2012059598A2 (en) 2012-05-10
EP4116325A1 (en) 2023-01-11
JP2023109910A (ja) 2023-08-08
IL225309B (en) 2021-05-31
CN103189074A (zh) 2013-07-03
US20130209480A1 (en) 2013-08-15
US20210128726A1 (en) 2021-05-06
LT3111954T (lt) 2019-07-10
US20230293683A1 (en) 2023-09-21
DK3111954T3 (da) 2019-07-15
TW201517917A (zh) 2015-05-16
US10363307B2 (en) 2019-07-30
US20180008706A1 (en) 2018-01-11
HRP20191162T1 (hr) 2019-10-04
RU2582937C2 (ru) 2016-04-27
BR112013011176A2 (pt) 2020-09-01
SI3111954T1 (sl) 2019-08-30
CY1121802T1 (el) 2020-07-31
JP2017002064A (ja) 2017-01-05
JP2021104995A (ja) 2021-07-26
RU2013125775A (ru) 2014-12-10
JP6515168B2 (ja) 2019-05-15
IL282625A (en) 2021-06-30
US9744234B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
PL3111954T3 (pl) Sposoby leczenia zesztywniającego zapalenia stawów kręgosłupa z zastosowaniem przeciwciał anty-il-17
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
PT2768857T (pt) Métodos para purificar anticorpos
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
HK1195320A1 (en) Antibodies for treatment of cancer expressing claudin
IL229254A0 (en) Therapeutic antibodies
IL249501B (en) A process for creating antibodies
HK1182625A1 (en) Bispecific antibodies
ZA201403108B (en) Purification of anti-c-met antibodies
EP2658970A4 (en) EXPRESS HUMANIZATION OF ANTIBODIES
EP2668206A4 (en) GENETIC MODIFICATION OF DOMAINS OF IMMUNOGLOBULINS
EP2542258A4 (en) MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
SG11201400405TA (en) Caninised antibodies and method for the production of same
HK1201537A1 (en) Anti-kdr antibodies and methods of use -kdr
EP2616812A4 (en) METHOD FOR TREATING AUTOIMMUNE DISEASES WITH ANTI-FCERI ANTIBODIES
EP2714713A4 (en) PURIFICATION OF ANTIBODIES
GB201020045D0 (en) Method for the treatment of biogas
HK1184173A1 (en) Anti-kdr antibodies and methods of use -kdr
IL226040A0 (en) Methods for generating antibodies to metalloenzymes
ZA201308992B (en) Therapeutic antibodies